Icon launches new electronic financial disclosure form software

Icon estimates the software can cut costs more than 50% compared to traditional form managment methods. (Icon)

Icon has launched a new, paperless solution for managing the clinical investigator financial disclosure forms mandated by the FDA.

The Dublin-based contract research organization’s Firecrest Financial Disclosure software allows sponsors to electronically gather, distribute, track and manage completion of the forms, required under 21 CFR Part 54, ahead of the study start-up process.

Icon hopes the system will lower the risks of regulatory noncompliance and reduce administrative costs compared to traditional distribution and tracking, the company said in a statement.

Survey

Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

“We estimate the solution is capable of delivering savings in excess of 50% when compared to traditional methods, while also contributing to the environmental sustainability targets of our clients,” said Mark Connolly, vice president for Firecrest systems at Icon.

Icon developed the software to address ongoing compliance challenges in the industry due to incomplete forms, the company said.

Icon first acquired Firecrest Clinical in 2011, and now offers a suite of web-based software including electronic consent forms and biometrics, patient prescreening, document tracking and site staff training and guides.

Suggested Articles

Data firm Syapse has begun working with the FDA to help bring real-world evidence to bear on the agency’s decisions to approve cancer drugs.

The People-Centered Research Foundation tapped Datavant to de-identify real-world data across its national clinical research network.

Boehringer Ingelheim and MD Anderson Cancer Center have joined forces to create a “virtual” R&D hub so the pair can work on cancer drugs.